Stockholders Approve Massive Share Increase, Two Reverse Splits, and $10.8M Debt Conversion
JAGX sits 31% above its 52-week low of $0.313 on light trading volume (0.3× avg).
Summary
Jaguar Health stockholders approved a substantial increase in authorized shares, two potential reverse stock splits, and the issuance of shares to convert a $10.8 million secured promissory note, signaling significant future dilution and ongoing efforts to address financial distress and Nasdaq compliance.
Key Events · Financing and Capital Events · JAGX
-
Authorized Share Increase Approved
Stockholders approved increasing authorized common stock from 298,000,000 to 500,000,000 shares, and total authorized shares from 352,475,074 to 554,475,074 shares. If all authorized shares were issued, dilution would be approximately 3926% based on current outstanding shares of 12,419,277.
-
Two Reverse Stock Splits Authorized
Stockholders approved two separate potential reverse stock splits, each at a ratio between 1-for-15 and 1-for-150. These splits can be implemented at the board's discretion within one year, indicating proactive measures to address Nasdaq's minimum bid price requirement.
-
$10.8 Million Debt-to-Equity Conversion Approved
Approval was granted to issue common stock upon the exchange of a $10,810,000 secured promissory note held by Streeterville Capital, LLC. This conversion is highly dilutive, representing over 200% of current outstanding shares.
Analysis · JAGX · Life Sciences
This 8-K details critical stockholder approvals that directly address Jaguar Health's severe financial challenges and Nasdaq listing requirements, as previously highlighted in its recent 10-K. The authorization to increase common stock by over 200 million shares, coupled with the approval of two potential reverse stock splits, provides the company with significant flexibility for future capital raises and maintaining its stock price above minimum listing requirements. However, these measures also pave the way for extreme dilution. The approval to issue shares for the $10.8 million Streeterville Capital note conversion is particularly impactful, representing over 200% dilution relative to current outstanding shares. Investors should anticipate significant dilution as the company utilizes these authorizations to manage its debt and secure necessary funding.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.31 to $15.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.